In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Gleevec Shows Innovation Sells-Even in Europe

Executive Summary

While the pharmaceutical industry bemoans the European climate, with its pricing and reimbursement challenges and rationing of access to drugs, Novartis' experience with Gleevec shows that with a truly innovative product that clearly addresses an unmet medical need, it's not impossible to do well in Europe.

You may also be interested in...



Imbalanced Innovation: The High Cost of Europe's "Free Ride"

By keeping pharmaceutical prices and utilization artificially low, Europe is losing more economically than it gains, says consulting group Bain & Co. Here's why-and what the drug industry should do about it

Lundbeck: Cipralex Falters in Europe

Lundbeck had appeared well prepared to meet the challenge of losing patent protection on its biggest selling drug, anti-depressant Cipramil. Switching patients to single isomer follow-on Cipralex before generic Cipramil could take hold worked for US marketing partner Forest. But getting follow-on products to market in cost-conscious, skeptical Europe is far harder, as Lundbeck is now learning to its cost.

Senexis Ltd.

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel